Incyte buys Vega Therapeutics for US$2B to boost rare bleeding disorder pipeline

USA—Incyte has agreed to acquire Vega Therapeutics in a deal valued at up to US$2 billion, strengthening its position in rare blood disorder treatments.

The agreement includes an upfront payment of US$1.25 billion, with additional milestone-based payments of up to US$750 million tied to future sales performance.

The acquisition comes through Vega’s parent company, Star Therapeutics, and gives Incyte full rights to VGA039, a late-stage investigational therapy targeting bleeding disorders, including von Willebrand disease (VWD).

Pipeline candidate advances into Phase III development

VGA039, also known as latarcibart, is currently being evaluated in the pivotal Phase III VIVID-6 study (NCT07115004).

The therapy is being developed as a self-administered, subcutaneous injection designed for monthly dosing, a format intended to improve treatment convenience for patients who often rely on frequent intravenous infusions.

Vega is also exploring additional indications beyond VWD, although these remain in preclinical development.

While the company has not disclosed specific conditions, the broader focus includes other rare bleeding disorders that share similar coagulation challenges.

Mechanism targets Protein S to restore clotting balance

The therapy works by modulating Protein S, a naturally occurring anticoagulant that helps regulate clot formation.

By inhibiting its cofactor activity in specific coagulation pathways, VGA039 aims to enhance platelet adhesion and improve fibrin deposition, ultimately supporting more effective blood clotting in patients with bleeding disorders.

Researchers believe this mechanism could benefit individuals across multiple forms of VWD, a condition that affects blood clotting due to deficiencies or dysfunction in von Willebrand factor.

Competitive landscape in von Willebrand disease

If approved, VGA039 would compete in a market served by Takeda’s Vonvendi, a recombinant von Willebrand factor therapy, and Octapharma’s Wilate, a plasma-derived product that combines von Willebrand factor with clotting factor VIII.

At present, treatment options remain limited, with desmopressin being the only widely used subcutaneous option for certain patients.

The drug acts as a selective vasopressin V2 receptor agonist and is commonly used in prophylactic clinical settings.

Incyte’s broader haematology strategy

Incyte executives say VGA039’s monthly dosing schedule and early clinical data could offer a competitive advantage by reducing treatment burden and improving quality of life for patients requiring long-term care.

CEO Bill Meury highlighted the therapy’s “first-in-class profile” as a potential growth driver for the company’s expanding haematology portfolio.

The asset would complement Incyte’s flagship blood cancer drug Jakafi (ruxolitinib), which currently anchors its haematology business in the United States.

The drug faces patent expiry in 2028, prompting the company to strengthen its pipeline ahead of potential revenue pressure.

Outside the US, ruxolitinib is marketed by Novartis under the brand name Jakavi, continuing its global role in treating myelofibrosis and related conditions.